Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

By S. Connolly, Janice Pogue, R. Hart, S. Hohnloser, M. Pfeffer, S. Chrolavicius, S. Yusuf. New England Journal of Medicine, 2009

1,867 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. (2014, background): “Patients in whom clopidogrel therapy was indicated were also excluded to minimize the confounding variable of chronic thienopyridines, which potentially could influence the incidence of stroke, thromboembolism, or bleeding (20).”
Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). (2013, methodology): “Clopidogrel has been reported to reduce ischemic stroke by 32% (13).”
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, background): “Aspirin–clopidogrel combination therapy has additional efficacy, compared with aspirin monotherapy, but at additional risk for major bleeding.(26) Thus, aspirin monotherapy should be confined to those who refuse any OAC and cannot tolerate aspirin–clopidogrel combination therapy due, for example, to”